Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies

Brigid S. Boland*, Benjamin Goodwin, Zeli Zhang, Nathaniel Bloom, Yu Kato, Jennifer Neill, Helen Le, Tiffani Tysl, Angelina E. Collins, Parambir S. Dulai, Siddharth Singh, Nghia H. Nguyen, Alba Grifoni, Alessandro Sette, Daniela Weiskopf, John T. Chang, Jennifer M. Dan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.

Original languageEnglish (US)
Pages (from-to)E00484
JournalClinical and translational gastroenterology
Volume13
Issue number4
DOIs
StatePublished - Apr 28 2022

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies'. Together they form a unique fingerprint.

Cite this